We are a charity and rely on donations

Charity Number: 1117194 (England and Wales)

Registered Company: 06000961

Registered address:
Shift.ms, Platform, New Station Street, LS1 4JB, United Kingdom

London office:
Shift.ms, Somerset House, Strand, West Goods Entrance, London WC2R 1LA, United Kingdom

©2024 Shift.ms

@Bing15 

Last reply

Bing15

Ocrelizumab

Been asked to choose a med to start out of the list the neurologist told me about at my last appointment on Friday, I went for ocrevus, however since researching it on the nice website I’m now terrified or the “c” word! Does anyone have experience? Or advice? 🤞🏼
8
@Stumbler
@Stumbler
 

@bing15 , here's a recent press report :- https://multiplesclerosisnewstoday.com/2018/03/28/ms-experts-views-on-ocrevus-a-year-after-fda-approval/ When it comes to risks, forewarned is forearmed. So, monitoring can mitigate the risk.

@TheQuietLady
@TheQuietLady
 

Hi @bing15, yes I am researching it too! I have the choice of Ocrevus or Lemtrada, and was leaning towards Ocrevus but the consultant was saying about higher risk of breast cancer, I think because I am 48 and probably going through the menopause. It's difficult! Thanks for saying about the NICE website, I didn't think of that. Hopefully you can decide.